Abstract
The rapid escalation in the global prevalence diabetes, with more than 30% being afflicted with diabetic retinopathy (DR), means it is likely that associated vision-threatening conditions will also rise substantially. This means that new therapeutic approaches need to be found that go beyond the current standards of diabetic care, and which are effective in the early stages of the disease. In recent decades several new pharmacological agents have been investigated for their effectiveness in preventing the appearance and progression of DR or in reversing DR; some with limited success while others appear promising. This up-to-date critical review of non-traditional systemic treatments for DR is based on the published evidence in MEDLINE spanning 1980-December 2014. It discusses a number of therapeutic options, paying particular attention to the mechanisms of action and the clinical evidence for the use of renin-angiotensin system blockade, fenofibrate and calcium dobesilate monohydrate in DR.
Keywords: Calcium dobesilate, diabetic retinopathy, fenofibrate, renin-angiotensin system blockade.
Current Medicinal Chemistry
Title:Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review
Volume: 22 Issue: 21
Author(s): Rafael Simo, Stefania Ballarini, Jose Cunha-Vaz, Linong Ji, Hermann Haller, Paul Zimmet and Tien Y Wong
Affiliation:
Keywords: Calcium dobesilate, diabetic retinopathy, fenofibrate, renin-angiotensin system blockade.
Abstract: The rapid escalation in the global prevalence diabetes, with more than 30% being afflicted with diabetic retinopathy (DR), means it is likely that associated vision-threatening conditions will also rise substantially. This means that new therapeutic approaches need to be found that go beyond the current standards of diabetic care, and which are effective in the early stages of the disease. In recent decades several new pharmacological agents have been investigated for their effectiveness in preventing the appearance and progression of DR or in reversing DR; some with limited success while others appear promising. This up-to-date critical review of non-traditional systemic treatments for DR is based on the published evidence in MEDLINE spanning 1980-December 2014. It discusses a number of therapeutic options, paying particular attention to the mechanisms of action and the clinical evidence for the use of renin-angiotensin system blockade, fenofibrate and calcium dobesilate monohydrate in DR.
Export Options
About this article
Cite this article as:
Simo Rafael, Ballarini Stefania, Cunha-Vaz Jose, Ji Linong, Haller Hermann, Zimmet Paul and Wong Y Tien, Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review, Current Medicinal Chemistry 2015; 22 (21) . https://dx.doi.org/10.2174/0929867322666150520095923
DOI https://dx.doi.org/10.2174/0929867322666150520095923 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Haemodynamic Regulation of Gene Expression in Vascular Tissue Engineering
Current Vascular Pharmacology Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Meet Our Associate Editor:
Cardiovascular & Hematological Disorders-Drug Targets Targeting Leukostasis for the Treatment of Early Diabetic Retinopathy
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Proteomic Analysis of Plasma to Reveal the Impact of Short-Term Etanercept Therapy in Pediatric Patients with Enthesitis-Related Arthritis: A Case Report
Combinatorial Chemistry & High Throughput Screening Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation
Current Clinical Pharmacology Lipoprotein-Associated Phospholipase A2: How Effective as a Risk Marker of Cardiovascular Disease and as a Therapeutic Target?
Inflammation & Allergy - Drug Targets (Discontinued) Interstitial Lung Disease in Idiopathic Inflammatory Myopathy
Current Rheumatology Reviews Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design In the Search of the Vulnerable Plaque: Current Diagnostic Techniques and Future Directions
Vascular Disease Prevention (Discontinued) Herb-Drug Interactions in Neurological Disorders: A Critical Appraisal
Current Drug Metabolism Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) Enhancing Endothelial Progenitor Cell Function Through Selective Estrogen Receptor Modulation: A Potential Approach to Cardiovascular Risk Reduction
Cardiovascular & Hematological Agents in Medicinal Chemistry Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use)
Current Vascular Pharmacology Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Current Medicinal Chemistry